ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
-0,01%
Bitcoin
67.686,80
0,30%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. AMEX
  6. NovaBay Pharmaceuticals Inc New (NBY)

  7. NovaBay Pharmaceuticals Inc New (NBY) News

NBY

NovaBay Pharmaceuticals (NBY)

NovaBay Pharmaceuticals Inc New
Von:
Sortieren nach:
 Showing the most relevant articles for your search:AMEX:NBY
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202422h50Edgar (US Regulatory)Form 8-K - Current reportAMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202422h43Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]AMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202403h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202403h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202403h27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202403h24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NBYNovaBay Pharmaceuticals Inc New
31/05/202403h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NBYNovaBay Pharmaceuticals Inc New
29/05/202423h27Edgar (US Regulatory)Form 8-K - Current reportAMEX:NBYNovaBay Pharmaceuticals Inc New
29/05/202423h22Business WireNovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate UpdatesAMEX:NBYNovaBay Pharmaceuticals Inc New
13/05/202414h30Business WireNovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye SymptomsAMEX:NBYNovaBay Pharmaceuticals Inc New
09/05/202422h05Business WireNovaBay Pharmaceuticals Reports First Quarter 2024 Financial ResultsAMEX:NBYNovaBay Pharmaceuticals Inc New
07/05/202414h00Business WireNovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through AmazonAMEX:NBYNovaBay Pharmaceuticals Inc New
03/05/202412h50Business WireNovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024AMEX:NBYNovaBay Pharmaceuticals Inc New
22/04/202412h57Business WireNovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova SalesAMEX:NBYNovaBay Pharmaceuticals Inc New
20/04/202400h00Business WireNovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder EquityAMEX:NBYNovaBay Pharmaceuticals Inc New
17/04/202412h59Business WireNovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing ExpensesAMEX:NBYNovaBay Pharmaceuticals Inc New
26/03/202421h05Business WireNovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial ResultsAMEX:NBYNovaBay Pharmaceuticals Inc New
25/03/202423h38Business WireNovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024AMEX:NBYNovaBay Pharmaceuticals Inc New
14/03/202413h00Business WireNovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023AMEX:NBYNovaBay Pharmaceuticals Inc New
14/02/202420h52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:NBYNovaBay Pharmaceuticals Inc New
06/02/202417h52Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:NBYNovaBay Pharmaceuticals Inc New
30/01/202415h00Business WireNovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based SalesAMEX:NBYNovaBay Pharmaceuticals Inc New
10/01/202414h00Edgar (US Regulatory)Form 8-K - Current reportAMEX:NBYNovaBay Pharmaceuticals Inc New
09/01/202415h15Business WireNovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor NetworkAMEX:NBYNovaBay Pharmaceuticals Inc New
04/01/202417h50Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesAMEX:NBYNovaBay Pharmaceuticals Inc New
21/12/202313h58Edgar (US Regulatory)Form 8-K - Current reportAMEX:NBYNovaBay Pharmaceuticals Inc New
11/12/202322h32Edgar (US Regulatory)Form 8-K - Current reportAMEX:NBYNovaBay Pharmaceuticals Inc New
06/12/202312h50Business WireNovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic MembranesAMEX:NBYNovaBay Pharmaceuticals Inc New
09/11/202322h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NBYNovaBay Pharmaceuticals Inc New
09/11/202322h05Business WireNovaBay Pharmaceuticals Reports Third Quarter 2023 Financial ResultsAMEX:NBYNovaBay Pharmaceuticals Inc New
 Showing the most relevant articles for your search:AMEX:NBY

Kürzlich von Ihnen besucht

NYSE
CLNS-C
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten